Altieri D C, Edgington T S
Department of Immunology, Research Institute of Scripps Clinic, La Jolla, CA 92037.
J Immunol. 1990 Jul 1;145(1):246-53.
Mitogenesis, cell differentiation and immune-inflammatory responses are regulated by the coordinated assembly of proteases with specific cellular receptors. We have investigated the possibility that immune effector cells may express a high-affinity protease receptor. To address this hypothesis, we have generated mAb to factor V and its activated form Va, a circulating plasma protein that binds the serine protease of the coagulation cascade, factor Xa. Further, by flow microfluorimetry screening, we have isolated a panel of these mAb that recognize a surface molecule expressed on transformed monocytic cells. We now show that these mAb bind to blood monocytes, to CD3- CD16+ CD56+ NK cells, and with considerable heterogeneity, to neutrophils. A small subset of CD3+ cells (5 to 10%) was also identified by these probes and further phenotypically characterized by two-color flow microfluorimetry as predominantly coexpressing CD2, CD4 or CD8, CD57, CD11b, and alpha/beta TCR. This subset of CD3+ cells was expanded in vitro by both lectin- or Ag-specific stimulation. In addition, long term alloreactive stimulation resulted in approximately 8- to 10-fold increased expression of the molecule recognized by these mAb. Functional analyses were performed on a selected T cell clonal derivative of the transformed cell line HuT 78. These cells bound 125I-factor Xa in a specific reaction saturated at 194,000 +/- 26,000 molecules/cell with a Kd approximately 10 to 20 nM and inhibited by the mAb panel described above. These data suggest that immune effector cells express a dynamically regulated protease receptor that is immunologically related to the plasma coagulation protein factor V and its activated form Va. We propose the term effector cell protease receptor-1 to tentatively identify this molecule, and we speculate on its possible involvement in specialized protease-mediated effector functions.
有丝分裂、细胞分化和免疫炎症反应是由蛋白酶与特定细胞受体的协同组装来调节的。我们研究了免疫效应细胞可能表达高亲和力蛋白酶受体的可能性。为了验证这一假设,我们制备了针对因子V及其活化形式Va的单克隆抗体,因子V是一种循环血浆蛋白,可结合凝血级联反应中的丝氨酸蛋白酶因子Xa。此外,通过流式微荧光筛选,我们分离出一组识别转化单核细胞表面表达分子的单克隆抗体。我们现在表明,这些单克隆抗体可与血液单核细胞、CD3-CD16+CD56+自然杀伤细胞结合,并且以相当大的异质性与中性粒细胞结合。这些探针还鉴定出一小部分CD3+细胞(5%至10%),并通过双色流式微荧光进一步表型分析,发现其主要共表达CD2、CD4或CD8、CD57、CD11b和α/βT细胞受体。这一CD3+细胞亚群在体外通过凝集素或抗原特异性刺激而扩增。此外,长期的同种异体反应性刺激导致这些单克隆抗体识别的分子表达增加约8至10倍。对转化细胞系HuT 78的一个选定T细胞克隆衍生物进行了功能分析。这些细胞以特异性反应结合125I-因子Xa,在194,000±26,000个分子/细胞时达到饱和,解离常数约为10至20 nM,并受到上述单克隆抗体组的抑制。这些数据表明,免疫效应细胞表达一种动态调节的蛋白酶受体。该受体在免疫学上与血浆凝血蛋白因子V及其活化形式Va相关。我们提出术语“效应细胞蛋白酶受体-1”来初步鉴定该分子,并推测其可能参与特殊的蛋白酶介导的效应功能。